Alzheimer’s disease (AD), marked by severe memory loss is a deadly degenerative disease affecting the nerves. Concerns are high on its rapid spread among vast sections of the global population.
The external features of AD manifest as progressive loss of cognitive and motor activities and a gradual slowing of language skills with unusual hardship in identifying persons and objects.
This neural disease stems from the increased accumulation of β amyloid peptide (Aβ) and hyperphosphorylated Tau protein depositing as plaques in the nervous system. Follow Oncotarget on Twitter.
Alzheimer’s and Obesity
Rough estimates suggest that 35 million people are affected by the AD, and the number is increasing. Scientists are curious to trace any link between obesity that is rampant in developed countries and the rapid spread of AD.
The malaise of obesity has gripped the developed world. In simple terms, obesity might be a common nutritional disorder, but it is a severe health hazard impinging on cognitive abilities.
Many studies have linked obesity to diminishing cognitive performance and dipping brain volumes. They further lead to severe cognitive decline including AD if patients are obese and afflicted with other metabolic diseases. Download output styles at Endnote.com
The risk of the AD is high with patients with Type 2 Diabetes (T2D) according to Rotterdam studies. However, no mechanism is in sight that links obesity and AD. Also, no molecular system has connected obesity’s relation with brain deviation appearing with the AD.
The success of Oncotarget has prompted us to launch sections beyond oncology – https://t.co/ccRO4O68Oj
— Oncotarget (@OncotargetJrnl) December 14, 2017
Among the factors contributing to obesity, a high dose of APP in adipose tissue and high incidence of Aβ in plasma are significant which also step up high insulin resistance. Some studies have attributed obesity to causing T2D and insulin resistance.
New Therapy for PTC Cancer
For a cancer patient, the severest shock will be to learn that the cancer is drug-resistant and becoming incurable.
This dilemma is most acute among papillary thyroid carcinoma (PTC) patients where the drug resistance is appalling. As a frequent thyroid cancer, the drug vemurafenib treats PTC.
Now there is good news for PTC patients. Findings by a Harvard Medical School team says palbociclib, an FDA-approved drug that treats breast cancer can check the drug resistance to vemurafenib.
The findings published in Oncotarget notes that the BRAF gene’s mutation activates PTC that vemurafenib neutralizes selectively.
Despite the early progress with vemurafenib in treating PTC, drug resistance creeps in the later phase making cancer grow and spread further.
The study’s principal author, Carmelo Nucera, who is an assistant professor at Harvard Medical School said the findings have discovered that a combined drug therapy involving vemurafenib and palbociclib could make a viable therapeutic impact on the PTC patients.